Table 2.

Proportion of cases with outcome treatment completion or died, categorized by FLD and SLD resistance

FLD resistance	% of patients with reported SLD resistance vs. % of patients without SLD resistance Other SLDs
	Fluoroquinolones		Injectables		Other SLDs
	Successful treatment completion %	Died %	Successful treatment Completion %	Died %	Successful treatment completion %	Died %
INH-susceptible, rifamycin-susceptible	84.7 vs. 90.0	15.3 vs. 10.0	86.8 vs. 88.9	13.2 vs. 11.1	87.5 vs. 88.4	12.5 vs. 11.6
INH-resistant, rifamycin-susceptible	87.8 vs. 92.8	12.2 vs. 7.2	97.8 vs. 92.0	2.2 vs. 8.0	91.3 vs. 91.8	8.7 vs. 8.2
INH-resistant, rifamycin-resistant	72.9 vs. 76.1	27.1 vs. 23.9	57.2 vs. 77.1*	42.8 vs. 22.9*	74.9 vs. 77.8	25.1 vs. 22.2
INH-susceptible, rifamycin-resistant	60.0 vs. 68.0	40.0 vs. 32.0	50.0 vs. 67.5	50.0 vs. 32.5	64.5 vs. 67.0	35.5 vs. 33.0

^*P < 0.005.

FLD = first-line drug; SLD = second-line drug; INH = isoniazid.